1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,388 | 0,415 | 09:04 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 05.11. | Tevogen Bio Inc: Tevogen Reports Major Clinical Milestone: Expands HLA Coverage of its Investigational Precision T Cell Therapy for Acute and Long COVID | 58 | GlobeNewswire (Europe) | This milestone expands patient eligibility through multi-HLA targetingBuilds on completed TVGN 489 trial demonstrating 100% viral clearance, no reinfections, and no cases of Long COVID in high-risk... ► Artikel lesen | |
| 03.11. | Tevogen Bio Inc: Tevogen Clarifies Reported Financials, Highlighting Strong Capital Efficiency and Low Cash Burn | 69 | GlobeNewswire (Europe) | WARREN, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN), today issued a statement to provide clarity regarding its accumulated deficit reported... ► Artikel lesen | |
| 29.10. | Tevogen Bio Inc: Tevogen Senior Management Engages with Business and Community Leaders and Highlights Recent Progress | 301 | GlobeNewswire (Europe) | WARREN, N.J., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN), in ongoing community, industry, and academic engagements, has continued to underscore... ► Artikel lesen | |
| 15.10. | Tevogen Bio Inc: Tevogen Updates on TVGN 489 Following Growing Long COVID Patient Interest | 300 | GlobeNewswire (Europe) | Company intends to collaborate with government initiatives, Long COVID patient organizations, and major healthcare providers to expedite development of TVGN 489In recognition of the high volume of... ► Artikel lesen | |
| 26.09. | Tevogen Bio Holdings verstößt gegen NASDAQ-Mindestkursanforderung | 4 | Investing.com Deutsch | ||
| TEVOGEN BIO Aktie jetzt für 0€ handeln | |||||
| 26.09. | Tevogen Bio Holdings Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 25.09. | Tevogen Bio Inc: Tevogen Marks Major Milestone in Its AI Initiative to Enhance Efficacy of T Cell-Based Therapies with 100x PredicTcell Beta Data Expansion | 162 | GlobeNewswire (Europe) | Beta version of PredicTcell expands training dataset to ~1.4 million and total dataset to over 6.7 billion records.Potential future T cell therapies could reliably bind to their target nearly every... ► Artikel lesen | |
| 23.09. | Tevogen Bio Inc: Tevogen Highlights Potential Role of TVGN 489 in Eliminating Persistent Viral Reservoirs Linked to Long COVID | 1 | GlobeNewswire (USA) | ||
| 19.09. | Tevogen Bio Inc: Tevogen Commends HHS for Addressing Long COVID, Emphasizes TVGN 489's Potential Impact for 20 Million Americans | 1 | GlobeNewswire (USA) | ||
| 10.09. | Tevogen Bio Inc: Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Join Startup Forum Panel at Databricks DATA + AI World Tour in Boston | 1 | GlobeNewswire (USA) | ||
| 09.09. | Tevogen Bio Inc: Tevogen Estimates 5-Year Top-Line Revenue of ~$6.5 Billion For Product Focused on Liver Cancer Prevention with High-Risk Chronic Hepatitis B Infection | 108 | GlobeNewswire (Europe) | Risk adjusted Net Present Value (rNPV) for TVGN 116 is estimated to exceed ~$325 million in the US alone. WARREN, N.J., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company")... ► Artikel lesen | |
| 08.09. | Tevogen announces $9-11 billion valuation for COVID-19 T cell therapy | 2 | Investing.com | ||
| 08.09. | Tevogen Bio Inc: Tevogen Values TVGN-489 at $9-$11 Billion rNPV, Its First Clinical Product From the Proprietary ExacTcell Allogeneic T Cell Platform | 177 | GlobeNewswire (Europe) | WARREN, N.J., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN), today shared the risk-adjusted net present value (rNPV) estimate of $9 billion to... ► Artikel lesen | |
| 04.09. | Tevogen shares EBV treatment forecast with $3.5 billion revenue potential | 2 | Investing.com | ||
| 04.09. | Tevogen Bio Inc: Tevogen Shares Valuation of Key Assets and Potential Forecast For Pipeline Product Focused on EBV Associated Leukemia and Lymphomas | 115 | GlobeNewswire (Europe) | The risk adjusted Net Present Value (rNPV) for TVGN 930 is estimated to exceed ~$250 million in the US alone.Covering five rare disease eligible indications, the accessible market in the US could... ► Artikel lesen | |
| 03.09. | Tevogen highlights need for SARS-CoV-2 treatments for immunocompromised | 2 | Investing.com | ||
| 03.09. | Tevogen Bio Inc: Tevogen Underscores the Importance of Precision Immunotherapies, Including TVGN 489 for Vulnerable Individuals Infected with SARS-CoV-2 | 114 | GlobeNewswire (Europe) | WARREN, N.J., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN), today highlighted the continuing need for SARS-CoV-2 treatments for individuals... ► Artikel lesen | |
| 27.08. | Tevogen Bio Inc: Tevogen Bio Highlights Proprietary Assets and Upcoming Valuation Disclosure | 139 | GlobeNewswire (Europe) | WARREN, N.J., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN), today updated investors of its significant internally developed assets, which under... ► Artikel lesen | |
| 26.08. | Tevogen Bio Inc: Tevogen Expresses Gratitude to Yale for Recognition of Dr. Ryan Saadi and Company's Mission of Health Equity | 1 | GlobeNewswire (USA) | ||
| 25.08. | Tevogen Bio Inc: Tevogen Sees Continued Growth in Institutional Ownership in Q2 2025; 72% of Holders Increased or Maintained Positions | 234 | GlobeNewswire (Europe) | WARREN, N.J., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN), today announced an update on institutional ownership of the Company's outstanding... ► Artikel lesen |
1 2 3 4 5 Weiter >>
87 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 38,525 | +0,40 % | BERENBERG stuft QIAGEN NV auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat das Kursziel für Qiagen anlässlich der jüngst präsentierten Quartalszahlen von 50 auf 46 Euro gesenkt, die Einstufung aber auf "Buy" belassen.... ► Artikel lesen | |
| AMGEN | 290,55 | +0,12 % | Amgen nach Zahlen: Aktie geht steil. Die nächsten Kursziele | Das US-amerikanische Biotechunternehmen Amgen legte am Dienstag (04. November) die Finanzergebnisse für das 3. Quartal 2025 vor. In der Vergangenheit wusste das Unternehmen mit seinen Finanzergebnissen... ► Artikel lesen | |
| NOVAVAX | 6,211 | +0,05 % | Novavax, Inc.: Novavax Reports Third Quarter 2025 Financial Results and Operational Highlights | Total revenue of $70 million in the third quarter of 2025
Continued successful execution of Sanofi partnership with $225 million in milestones achieved year-to-date... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 11,990 | 0,00 % | Palatin Technologies, Inc.: Palatin Technologies Announces Pricing of Upsized $15.8 Million Public Offering | $15.8 million at closing with up to an additional $15.8 million upon the cash exercise of the milestone related warrants
Regains compliance with NYSE American... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 589,80 | +0,24 % | Regeneron Reports Promising Phase 2 Results For Novel Factor XI Antibodies In Knee Surgery Patients | WASHINGTON (dpa-AFX) - Regeneron Pharmaceuticals Inc. (REGN) announced encouraging results from two Phase 2 clinical trials evaluating its investigational factor XI antibodies-REGN7508Cat and... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,700 | +0,59 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Third Quarter 2025 Financial Results and Recent Business Highlights | Completed rolling Biologics License Application (BLA) submission seeking accelerated approval for lead candidate INO-3107; requested priority review
Expect... ► Artikel lesen | |
| SIRONA BIOCHEM | 0,037 | -100,00 % | Sirona Biochem Corp.: Sirona Biochem Update to Shareholders on Financial Status and Operations | VANCOUVER, British Columbia, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) ("Sirona") wishes to provide shareholders with a critical update on the company's financial... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 1,930 | +1,05 % | COSCIENS Biopharma Inc. Reports Third Quarter 2025 Financial Results and Provides Strategic Initiatives Update | COSCIENS voluntarily delists from Nasdaq, while retaining the Company's listing on the TSX COSCIENS restructuring results in significantly lower cash outflow with operating expenses down 59% vs. Q3... ► Artikel lesen | |
| BIOMARIN PHARMACEUTICAL | 47,560 | -0,36 % | Stifel stuft BioMarin-Aktie wegen Sorgen um Voxzogo auf "Halten" herab | ||
| NUREXONE BIOLOGIC | 0,453 | +2,49 % | NurExone unter den Finalisten: Mit Exosomen-Therapie ins Zentrum der Wissenschaftselite | ||
| ARROWHEAD PHARMACEUTICALS | 35,920 | +0,50 % | Arrowhead Pharmaceuticals vor FDA-Entscheidung: Attraktive Kaufchance? | Arrowhead Pharmaceuticals steht kurz vor entscheidenden Weichenstellungen, die den langfristigen Erfolg des Unternehmens maßgeblich beeinflussen könnten. Rückenwind gibt's aktuell durch einen starken... ► Artikel lesen | |
| XOMA ROYALTY | 29,600 | +2,07 % | XOMA Royalty Corporation: XOMA Royalty Reports Third Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements | Business development: Secures royalty economic interests in two early stage partnered assets through XOMA Royalty's announced expected acquisition of LAVA Therapeutics. Company acquisitions: •Completed... ► Artikel lesen | |
| PHIO PHARMACEUTICALS | 1,590 | 0,00 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals to Present Recent Clinical Results from Skin Cancer Trial with siRNA based INTASYL PH-762 | King of Prussia, Pennsylvania--(Newsfile Corp. - November 7, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its... ► Artikel lesen | |
| T2 BIOSYSTEMS | 0,250 | 0,00 % | NSE/A - T2 Biosystems, Inc. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | ||
| MOSAIC IMMUNOENGINEERING | - | - | Mosaic ImmunoEngineering Inc. - 10-Q, Quarterly Report |
Das Unternehmen TEVOGEN BIO HOLDINGS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +8,91 % bei einem Aktienkurs von 0,440 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TEVOGEN BIO HOLDINGS INC finden Sie auf Wallstreet Online.